Simplified Chinese
Tender Notice for the Civil Defense Works of the Minhai Biotechnology New Vaccine Internationalization Industrial Base Construction Project
Release date:
2020-07-30
Author:
Source:
Abstract
I. Project Name Minhai Biotechnology’s New Vaccine International Industrial Base Construction Project
II. Project Overview:
The Minhai Biologics International Vaccine Industrial Base Project, invested in and constructed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503-039, 040, 043, and 044 within the Daxing Biopharmaceutical Industry Base. The project’s boundaries are as follows: to the north, Simiao Road; to the south, the planned land‑use boundary (municipal green space); to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. The project is primarily dedicated to the research, development, and production of human vaccines.
Construction scale: Total land area of 90,013.218 m² 2 , with a total floor area of 187,684.83 m² 2 (Of which, the above-ground floor area is 130,410.84 m²) 2 , underground floor area 57,273.99 m² 2 ). The building has a height of 33.3 meters, with one basement level and seven above-ground floors. The basement floor-to-floor height is 6 meters, while the above-ground floors range from 3.8 to 7.9 meters in height. The green space ratio is 15%, the floor area ratio is 1.5, and the site coverage ratio is 40%.
Planned construction period for the civil defense project: September 2020 – September 2021.
III. Scope of the Tender:
The scope of this tender covers the civil defense engineering for the Minhai Biotechnology New‑Generation Vaccine Internationalization Industrial Base Project, including the fabrication and installation of civil defense door frames and doors, as well as the fabrication and installation of mechanical and electrical equipment within the civil defense facilities.
The civil defense area covers approximately 1,453 square meters and is designated as a Class II personnel shelter. It is located in the southeast corner of the first basement level, adjacent to the exterior wall.
IV. Registration Notes:
1. Participating entities shall submit the following documents: the business license of the legal entity, qualification certificates, the safety production license, a certificate of the legal representative or a letter of authorization from the legal representative, and copies of identification documents—four sets in total, with all copies stamped with the official seal of the entity—and shall clearly indicate the company’s registered capital.
2. Entities participating in the registration must possess the relevant professional qualifications.
3. Registration requires the provision of a contact person and contact information from the submitting organization. The contact person must be the project leader or an designated business liaison, and a 12-month social security certificate must be submitted.
4. The tendering entity will review the qualification documents submitted by registered entities, giving priority to those with relevant project experience, and will conduct further communication and on-site inspections with the shortlisted candidates.
5. Beijing Minhai Biotechnology Co., Ltd. was established in 2004 and is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s website.
V. Registration Address:
Beijing Minhai Biotechnology Co., Ltd. (No. 35 Simiao Road, Bio‑Pharmaceutical Industry Base, Daxing District, Beijing). Contact persons: Mr. Hao, Ms. Fang, and Mr. Wu from the New Project Department; contact numbers: 010-57864911 and 010-57864916.
VI. Registration Deadline: 5 August 2020, 17:30 hours.
Hereby announced!
Beijing Minhai Biotechnology Co., Ltd.
July 28, 2020
Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09